Large-cap Health Care company Novo Nordisk A/S has moved -1.4% so far today on a volume of 4,562,466, compared to its average of 4,821,804. In contrast, the S&P 500 index moved 1.0%.
Novo Nordisk A/S trades -2.32% away from its average analyst target price of $102.78 per share. The 3 analysts following the stock have set target prices ranging from $79.83 to $124.29, and on average have given Novo Nordisk A/S a rating of buy.
Anyone interested in buying NVO should be aware of the facts below:
-
Based on its trailing earnings per share of 2.44, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 41.1 while the S&P 500 average is 15.97
-
NVO has a forward P/E ratio of 32.2 based on its forward 12 month price to earnings (EPS) of $3.12 per share
-
The company has a price to earnings growth (PEG) ratio of 95.42 — a number near or below 1 signifying that Novo Nordisk A/S is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 4.83 compared to its sector average of 4.08
-
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
-
Based in Bagsvaerd, the company has 61,412 full time employees and a market cap of $458.64 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 6.9%.